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INTRODUCTION
Choriocarcinoma is a malignant tumor that is characterized by the secretion of the beta subunit of human choriogonadotropin (β-HCG). It is a common tumor of the ovary and testis, being developed from trophoblastic or totipotent germ cells [1, 2] . Choriocarcinoma can also occur in other organs such as the uterine body, brain (pineal gland), mediastinum, lung, retroperitoneum, urinary tract, liver, gallbladder, and gastrointestinal tract [1, 3] . Primary choriocarcinoma of the stomach (PCCS) is an extremely rare (0.08% of all gastric cancers) but aggressive tumor (survival below six months) in which histogenesis and therapeutic management are still undefined [1, 2] . PCCS was first described by Davidhon in 1905 and nominated as chorionepitheliom [4] . Until 2005, 142 cases of PCCS have been reported in total of which only 32 have been reported in English literature, with a male: female ratio of 2.3:1 [1, 2, 5] . The reported cases were predominantly diagnosed in patients over 60 years old, with about 40% of cases occurring in the lower third of the stomach, with direct pancreatic or duodenal invasion [1, 2] . Another 26 cases have been reported in English research literature between 2006 and 2018.
In this paper, we present a case of PCCS development in a male patient, and a hypothesis regarding the histogenesis of PCCS, based on the complex immunoprofile of the tumor cells and literature data.
CASE PRESENTATION
Chief complaints
A 66-year-old previously healthy male presented with epigastric pain and nausea.
History of present illness
Patient related two-week history of epigastric pain and nausea, without other significant symptoms.
History of past illness
He was an ex-smoker of four years and a social drinker. No other diseases were associated.
Personal and family history
No significant diseases were related.
Physical examination upon admission
Physical examination revealed scleral and cutaneous jaundice and hepatomegaly.
Laboratory examinations
All of the usually performed serum parameters were in normal limits. The serum value of tumor-specific markers such α-Fetoprotein (AFP), Carcinoembryonic Antigen (CEA), or HCG were not checked.
Imaging examinations
The CT scan showed a thickened posterior wall of the stomach at the pylorus, with periaortic lymphadenopathies and hepatic and pulmonary metastases. No other tumors of the breast, testis, mediastinum or peritoneum were described.
Histopathological assessment
Macroscopic examination of the 40 × 35 × 15 gastric specimen revealed a 33 mm × 33 mm × 15 mm ulcero-vegetative tumor, without lymph nodes in the surgical specimen. The 30 × 20 × 15 mm hepatic specimen was replaced by a whitish ill-defined tumor mass with necrosis and hemorrhages on cut section. Under microscope, in the mucosa, submucosa and muscularis propria of the stomach, proliferation of large dyscohesive and pleomorphic tumor cells and large hemorrhagic areas were seen. These cells proliferated, predominately surrounding large blood vessels. Multiple vascular emboli were also shown. Two types of cells were identified: Giant cells with lobulated or bizarre nuclei, similar to syncytiotrophoblastic cells, and oval cells with pale cytoplasm, with a similar aspect to cytotrophoblastic cells (Figure 1 ).
Immunohistochemical profile
Both types of tumor cells were diffusely marked by cytokeratin 7, MLH-1, MSH-2, PMS-2 and c-MET. The syncitiotrophoblastic-but not cytotrophoblastic cells showed diffuse positivity for inhibin and the plasma-cell-specific marker CD138 (Figure 2 ).
In one of the resection margins, a differentiated (G2) adenocarcinoma component was identified, which accounted for below 10% of the tumor and showed diffuse positivity for CDX2, cytokeratin 7, CEA and c-MET and focal positivity for cytokeratin 20 and CD138. A gradual transition between the two components was seen (Figure 2 ). The characteristics of the biomarkers used and complete immunohistochemical (IHC) profile of normal gastric mucosa and the two components of the tumor can be seen in Table 1 . It is necessary to mention the progressive loss of E-cadherin in both carcinoma components and tumor emboli. In emboli, CD138 and β-catenin positivity was displayed by the tumor cells but inhibin was negative. In emboli and hepatic metastasis, the choriocarcinoma component was identified.
FINAL DIAGNOSIS
Based on the histological aspect and immunoprofile of the tumor cells, the final diagnosis was gastric adenocarcinoma with choriocarcinomatous component, pT2NxM1L1V1R0 (Stage IV).
TREATMENT
Due to the obstructive effect of the hepatic metastases, urgent palliative gastrectomy with partial hepatic resection was performed, without preoperative biopsy. Signed informed consent for surgical intervention and publication of data was obtained before surgery.
OUTCOME AND FOLLOW-UP
The patient died one month after surgery. No chemotherapy was administered.
DISCUSSION
There are at least three theories regarding the histogenesis of PCCS. It was postulated that PCCS might originate from putative displaced gonadal anlage, from a teratoma or by retro-differentiation of adenocarcinoma [1] through the direction of embryonal ectoderm, retaining the ability to form trophoblasts [2] . As an adenocarcinoma component can be identified in 70% of PCCS [1] , such as in our case, and as an adenocarcinoma component can be infrequently founded in nodal metastasis [2] , we consider that PCCS is a dedifferentiated component of adenocarcinoma. In our case, CD138 positivity indicated a plasmacytoid component, as a possible multilineage (Table 1) . Although no hepatoid component was identified and AFP was negative, gastric mucosa showed positivity for both Hepar A and CD138. This aspect indicates the possible stemness features of gastric epithelial cells. In line with our hypothesis, the possible multilineage differentiation is proved by co-existence of other histological particular tumor types such as PCCS and small cell carcinoma [5] . Diagnosis of PCCS is difficult to conduct and is usually established in surgical specimens only. In bioptic specimens, the diagnosis of PCCS was reported in less than 15% of cases [1] . In serum, several markers might be elevated, such as HCG (reported preoperative values between 246 and 15500 mIU/mL) and/or AFP (approximately 50 mU/mL) [1] [2] [3] . Postoperative decreasing HCG value is seen in most of the cases [1] [2] [3] and can be used as a potential marker of recurrence [3] . Although the choriocarcinomatous component is CEA negative, such as in our case, the serum value of CEA can be higher than 20 ng/mL [3] , probably due to the adenocarcinoma component. The differential diagnosis should take into account both primary and metastatic tumors, based on imagistic investigation of the patient and the histological aspect, combined with the IHC profile. Metastases from a primary tumor of gonads (ovary, testes), endometrium or retroperitoneum must be excluded.
As approximately 70% of PCCS showed an adenocarcinoma component [1] , as in the present case, other rare variants of gastric carcinomas should be taken into account. The hepatoid variant was excluded based on negativity for hepatocyte paraffin 1 (Hep Par 1) and α-Fetoprotein [3] . Negativity of tumor cells for markers such as Cytokeratin 5/6 and p63 exclude the diagnosis of adenosquamous carcinoma, whereas negativity for vimentin and c-KIT (CD117) exclude a gastrointestinal stromal tumor [1] . The PCCS shows predominately systemic spread in the lungs, liver and peritoneum, but lymph node metastases are also associated [1] . Over 30% of the cases are diagnosed in the metastatic stage [3] , with direct pancreatic invasion [2] , such as in the present case.
As the histogenetic pathway is still unknown, there is no consensus regarding therapeutic strategies [6] . In the reported cases, the chemotherapics used for gestational choriocarcinoma were recommended [1] [2] [3] 6] . They include a BEP (Bleomycin, Etoposide, Cisplatin) regimen [1] , EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen [3] , DCF (docetaxel, cisplatin, 5-FU) regimen [6] , association of Cisplatin and Carboplatin [2] or Vinblastine, Ifosfomide and Cisplatin [1] . Folinic acid was also reported to be used [1, 2] but no complete answer can be obtained with the above nominated drugs [6] . Although no HER-2 positivity was seen in our case, the adenocarcinoma or choriocarcinoma component can show HER-2 gene amplification [3, 5] and targeted therapy with Trastuzumab combined with docetaxel and carboplatin can be done, with possible complete response [6] . In these cases, maintenance therapy with trastuzumab and capecitabine is indicated [6] . As positivity for PD-L-1 was shown in choriocarcinoma cells, these rare carcinomas might benefit by anti-PD-1 or anti-PD-L1 agents used for immunotherapy, such as nivolumab and pembrolizumab [7] .
CONCLUSION
Primary gastric choriocarcinoma is a rare variant of gastric adenocarcinoma that can show multilineage differentiation. Targeted therapy of this histological type still remains unknown. 
